New

Bovine IL-1 beta/IL-1F2 - Ready-to-Use ELISA Kit (Colorimetric)

Name: Bovine IL-1 beta/IL-1F2 - Ready-to-Use ELISA Kit (Colorimetric)
Brand: Novus Biologicals
SKU: NBP3-54974

Novus Biologicals | Catalog # NBP3-54974

Submit a review

Product Documents

Product Specifications
Precision
Kit Contents
Preparation & Storage
Background
Product Documents
Specific Notices
Research Areas

Key Product Details

Sample Type & Volume Required Per Well

Serum, plasma, tissue homogenates, cell lysates, cell culture supernatants and other biological fluids (100 uL)

Sensitivity

6.1 pg/mL (example only; lot dependent)

Assay Range

15.6 - 1000 pg/mL (example only; lot dependent)

View all IL-1 beta/IL-1F2 ELISA Kits »

Product Specifications

Assay Type

Sandwich ELISA

Kit Type

ELISA Kit (Colorimetric)

Species

Bovine

Description

The Ready-To-Use ELISA kit offers pre-diluted detection reagents and a shorter experimental time.
Assay Length: 3 hours

Precision

Intra-Assay Precision (Precision within an assay) %CV 10 (example only; lot dependent)

Inter-Assay Precision (Precision between assays) %CV 12 (example only; lot dependent)

Kit Contents for Bovine IL-1 beta/IL-1F2 - Ready-to-Use ELISA Kit (Colorimetric)

Pre-coated 96T strip plate, Plate sealer for 96 wells, Standard, Standard Diluent, Detection Solution A, Detection Solution B, TMB Substrate, Stop Solution, Wash Buffer (30 x concentrate), Instruction manual

Preparation and Storage

Stability & Storage

Storage of components varies. See protocol for specific instructions.

Background: IL-1 beta/IL-1F2

Interleukin-1 beta (IL-1 beta), also called IL-1F2, is a proinflammatory cytokine that functions in host defense following injury or inflammation (1-5). IL-1 beta is expressed by cells of the immune system such as monocytes, macrophage, neutrophils, and hepatocytes (1-3). Human IL-1 beta protein is expressed in the cytoplasm in an inactive precursor form (pro-IL-1 beta) which is 269 amino acids in length with a theoretical molecular weight of 31 kDa (1,4,6). Pro-IL-1 beta is cleaved by IL-1 converting enzyme (ICE), also called caspase-1, generating the 18 kDa mature, active protein that is secreted from cells (1,4,6). Pro-IL-1 beta is produced as a cellular response to molecular signals from pathogens and other processes termed pathogen associated molecular patterns (PAMPs) and damage associated molecular patterns (DAMPs) (1,2). PAMPs and DAMPs signal through pattern recognition receptors (PRRs) to induce formation of the inflammasome (1,2). The inflammasome is a multi-protein complex made of a PRR, such as Nod-like receptor family, pyrin domain containing 3(NLRP3), an adaptor, such as apoptosis-associated spec-like protein containing a CARD (ASC), and pro-caspase-1 (1-3,5). Assembly of the inflammasome enables cleavage of pro-caspase-1 into active caspase 1, followed by secretion of activate IL-1 beta (1-3,5).

IL-1 beta binding to its receptor IL-1RI and the downstream signaling contributes to a dual pathophysiological role (3). On one hand, IL-1 beta signaling activates immune cells and drives CD4+ T cell polarization to T helper type 1 (Th1) and Th17 cells, resulting in anti-tumor responses and mediation of acute inflammation (2,3). However, IL-1 beta also supports tumor growth and metastasis driven by multiple mechanisms including chronic inflammation, an immunosuppressive tumor microenvironment (TME), and angiogenesis (3). Additionally, IL-1 beta signaling been implicated in the pathogenesis of neuroinflammatory diseases of the central nervous system (CNS) such as multiple sclerosis (MS), Alzheimer's disease, and diabetic retinopathy (DR) (2). Mouse studies have shown regression of tumors treated with IL-1 as well as protective effects of IL-1 beta in instances of induced colitis and colon carcinoma (3). Conversely, blocking IL-1 beta has also shown promising effect in cancer treatment, especially when combined with chemotherapeutics (2,3). Approved IL-1 beta monoclonal antibody canakinumab has shown significant therapeutic promise in the treatment of DR (2). Given its multifaceted role in disease, IL-1 beta is a promising therapeutic target.

References

1. Lopez-Castejon G, Brough D. Understanding the mechanism of IL-1beta secretion. Cytokine Growth Factor Rev. 2011;22(4):189-195. https://doi.org/10.1016/j.cytogfr.2011.10.001

2. Mendiola AS, Cardona AE. The IL-1beta phenomena in neuroinflammatory diseases. J Neural Transm (Vienna). 2018;125(5):781-795. https://doi.org/10.1007/s00702-017-1732-9

3. Bent R, Moll L, Grabbe S, Bros M. Interleukin-1 Beta-A Friend or Foe in Malignancies?. Int J Mol Sci. 2018;19(8):2155. https://doi.org/doi:10.3390/ijms19082155

4. Krumm B, Xiang Y, Deng J. Structural biology of the IL-1 superfamily: key cytokines in the regulation of immune and inflammatory responses. Protein Sci. 2014;23(5):526-538. https://doi.org/10.1002/pro.2441

5. He Y, Hara H, Nunez G. Mechanism and Regulation of NLRP3 Inflammasome Activation. Trends Biochem Sci. 2016;41(12):1012-1021. https://doi.org/10.1016/j.tibs.2016.09.002

6. Uniprot (P01584)

Long Name

Interleukin 1 beta

Alternate Names

IL-1b, IL-1F2, IL1 beta, IL1B

Gene Symbol

IL1B

Additional IL-1 beta/IL-1F2 Products

Product Documents for Bovine IL-1 beta/IL-1F2 - Ready-to-Use ELISA Kit (Colorimetric)

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot or batch number in the search box below.

Product Specific Notices for Bovine IL-1 beta/IL-1F2 - Ready-to-Use ELISA Kit (Colorimetric)

This product is for research use only and is not approved for use in humans or in clinical diagnosis. ELISA Kits are guaranteed for 6 months from date of receipt.